SEC Form 4 · accession 0001618835-17-000002
Evofem Biosciences, Inc. · EVFM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Maria Feldman
Officer — VP Clinical Research & Operati
Period of report
Mar 2, 2017
Accepted (ET)
Mar 6, 2017 · 3:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618835
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.43 | Mar 2, 2017 | A | 90,000 | A | — | Mar 2, 2027 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1(i) One half of the option shares vest upon receipt and completed analysis of LIPO-202 CL-31 trial data and (ii) the remaining one half of the option shares vest at the earlier of (a) 12/31/2017 or (b) upon the event of a change in control.